We are live on ! Find out more

Opko Health

OPK

Market cap $1.1B

1.48 USD

0.00

0%

At close Updated Aug 24, 4:00 PM EDT

Pre-market

After hours

1.49

+0.01

0.68%

1 day

0%

5 days

7.25%

1 month

21.31%

3 months

14.73%

6 months

28.7%

Year to date

16.54%

1 year

6.47%

5 years

-60.85%

10 years

-83.98%

About: OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.

Employees: 2,275

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 52.6%

Neutral 42.1%

Negative 5.3%

Zacks Investment Research

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

Zacks Investment Research

OPK Raises $125 Million Against Royalties: What Investors Should Know

OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.

OPK Raises $125 Million Against Royalties: What Investors Should Know

Zacks Investment Research

Is OPK Worth Buying as Valuation Meets Improving Business Trends?

OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.

Is OPK Worth Buying as Valuation Meets Improving Business Trends?

Zacks Investment Research

OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?

OPKO Health's 12.4% monthly gain is backed by narrower losses and better margins, though profitability and clinical execution remain key risks.

OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?

Zacks Investment Research

OPKO Health Secures $125 Million Financing Against Mazdutide Royalties

OPK raises $125 million against mazdutide royalties, gaining non-dilutive capital while retaining longer-term royalty upside.

OPKO Health Secures $125 Million Financing Against Mazdutide Royalties

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

OPKO Health: Mazdutide And MDX-2201 Could Change Everything

On July 27, OPKO Health, Inc. released its Q2 numbers. So, OPK's revenue from transfer of IP and other increased 208% YoY to $46.1 million in Q2, driven by a Nicoya license amendment. Also, OPKO raised its full-year 2026 revenue guidance from $530-$560 million to $560-$585 million.

OPKO Health: Mazdutide And MDX-2201 Could Change Everything

Zacks Investment Research

OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know

OPKO Health (OPK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OPKO Health (OPK) Upgraded to Buy: Here's What You Should Know

The Motley Fool

Why Opko Health Stock Surged by 33% on Tuesday

Investors were also cheered by a substantial narrowing of the company's net loss. Ditto for the raised full-year revenue guidance.

Why Opko Health Stock Surged by 33% on Tuesday

Zacks Investment Research

OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates

OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.

OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates

See News Rankings

Price charts implemented using Lightweight Charts™